Other innovative lipid-modifying approaches include antisense oligonucleotides targeting apolipoprotein C3, angiopoietin-like protein 3, and lipoprotein(a) [Lp(a)]—such as pelacarsen and olpasiran—which demonstrate promising results in addressing genetically driven dyslipidemias. The gene discussed is APOC3; the disease is metabolic syndrome.